The end of dopamine agonist monotherapy

Basicallly it says

The editorial writers discuss the "levodopa phobia" or the reluctance to use levodopa because of a concern that it's toxic to remaining dopaminergic neurons. These fears have largely dissipated, but there remains the established concern about increased risk of motor complications.

This new study, they write, "will help to persuade physicians and reassure patients that the fears that have served as the groundwork in establishing levodopa phobia — that often results in patients experiencing unnecessary and easily managed disability and reduction in quality of life in the early years of their disease — are unfounded."

The study also found that levodopa came out on top on a range of other patient-rated outcome measures, including activities of daily living, cognition, communication, bodily discomfort, and the summary index, which is an overall score for the 10 PDQ-39 domains. 

Even though patients in the levodopa group reported benefits in many areas, they were more likely to develop dyskinesia than were those in the other groups (hazard ratio, 1.52; 95% CI, 1.16 - 2.00; P = .003).

"What this probably means is that early in the disease, developing dyskinesia isn't too serious; you can adjust the medication and minimize the impact it has on the patient," said Professor Gray. "I think perhaps that the impact of dyskinesia isn't as big as perhaps has been made out," and that other adverse effects may be more important.

Adverse effects that patients may consider more important than dyskinesia may include sleep disturbances, edema, and compulsive behavior that has been linked to dopamine agonists


Hello Turnip

Really good to hear from you again.This sounds very interesting but unfortunately it says the article can t be found
Bw samdog